|
Gene: C17orf80 |
Gene summary for C17ORF80 |
Gene summary. |
Gene information | Species | Human | Gene symbol | C17orf80 | Gene ID | 55028 |
Gene name | chromosome 17 open reading frame 80 | |
Gene Alias | HLC-8 | |
Cytomap | 17q25.1 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9BSJ5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55028 | C17orf80 | LZE4T | Human | Esophagus | ESCC | 1.70e-03 | 1.64e-01 | 0.0811 |
55028 | C17orf80 | LZE24T | Human | Esophagus | ESCC | 1.68e-09 | 2.24e-01 | 0.0596 |
55028 | C17orf80 | P1T-E | Human | Esophagus | ESCC | 7.11e-04 | 1.76e-01 | 0.0875 |
55028 | C17orf80 | P2T-E | Human | Esophagus | ESCC | 1.97e-10 | 2.23e-01 | 0.1177 |
55028 | C17orf80 | P4T-E | Human | Esophagus | ESCC | 1.05e-03 | 1.28e-01 | 0.1323 |
55028 | C17orf80 | P8T-E | Human | Esophagus | ESCC | 1.05e-18 | 1.84e-01 | 0.0889 |
55028 | C17orf80 | P9T-E | Human | Esophagus | ESCC | 3.05e-03 | 1.07e-01 | 0.1131 |
55028 | C17orf80 | P10T-E | Human | Esophagus | ESCC | 9.53e-09 | 1.58e-01 | 0.116 |
55028 | C17orf80 | P11T-E | Human | Esophagus | ESCC | 1.20e-09 | 3.54e-01 | 0.1426 |
55028 | C17orf80 | P12T-E | Human | Esophagus | ESCC | 9.67e-18 | 3.25e-01 | 0.1122 |
55028 | C17orf80 | P15T-E | Human | Esophagus | ESCC | 1.83e-09 | 2.22e-01 | 0.1149 |
55028 | C17orf80 | P16T-E | Human | Esophagus | ESCC | 4.30e-10 | 2.33e-01 | 0.1153 |
55028 | C17orf80 | P20T-E | Human | Esophagus | ESCC | 3.34e-15 | 3.22e-01 | 0.1124 |
55028 | C17orf80 | P21T-E | Human | Esophagus | ESCC | 5.02e-07 | 1.38e-01 | 0.1617 |
55028 | C17orf80 | P22T-E | Human | Esophagus | ESCC | 3.80e-07 | 1.69e-01 | 0.1236 |
55028 | C17orf80 | P24T-E | Human | Esophagus | ESCC | 2.94e-07 | 1.48e-01 | 0.1287 |
55028 | C17orf80 | P26T-E | Human | Esophagus | ESCC | 4.40e-09 | 2.14e-01 | 0.1276 |
55028 | C17orf80 | P27T-E | Human | Esophagus | ESCC | 4.44e-08 | 1.57e-01 | 0.1055 |
55028 | C17orf80 | P28T-E | Human | Esophagus | ESCC | 4.31e-06 | 1.43e-01 | 0.1149 |
55028 | C17orf80 | P30T-E | Human | Esophagus | ESCC | 1.89e-05 | 1.81e-01 | 0.137 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C17orf80 | insertion | Frame_Shift_Ins | novel | c.324_325insAGTGG | p.Asp109SerfsTer17 | p.D109Sfs*17 | Q9BSJ5 | protein_coding | TCGA-HD-8635-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
C17orf80 | SNV | Missense_Mutation | novel | c.670N>T | p.Pro224Ser | p.P224S | Q9BSJ5 | protein_coding | tolerated(0.07) | possibly_damaging(0.698) | TCGA-KC-A7F3-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 7 | Unknown | Unknown | SD |
C17orf80 | SNV | Missense_Mutation | c.530N>T | p.Ser177Leu | p.S177L | Q9BSJ5 | protein_coding | tolerated(0.22) | possibly_damaging(0.6) | TCGA-ZG-A9L0-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | SD | |
C17orf80 | SNV | Missense_Mutation | novel | c.1636N>G | p.Asn546Asp | p.N546D | Q9BSJ5 | protein_coding | tolerated(0.19) | benign(0.318) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C17orf80 | SNV | Missense_Mutation | rs764164900 | c.1567N>A | p.Gly523Arg | p.G523R | Q9BSJ5 | protein_coding | tolerated(1) | benign(0) | TCGA-CG-4305-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
C17orf80 | SNV | Missense_Mutation | novel | c.828N>T | p.Glu276Asp | p.E276D | Q9BSJ5 | protein_coding | tolerated(0.1) | possibly_damaging(0.894) | TCGA-D7-A6EY-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
C17orf80 | SNV | Missense_Mutation | rs200611765 | c.667G>A | p.Val223Met | p.V223M | Q9BSJ5 | protein_coding | tolerated(0.36) | benign(0.009) | TCGA-F1-A448-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR |
C17orf80 | deletion | Frame_Shift_Del | novel | c.1494delN | p.Glu500LysfsTer16 | p.E500Kfs*16 | Q9BSJ5 | protein_coding | TCGA-BR-A4QL-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | CR | ||
C17orf80 | SNV | Missense_Mutation | novel | c.1328C>A | p.Pro443His | p.P443H | Q9BSJ5 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-ET-A39R-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C17orf80 | insertion | Frame_Shift_Ins | novel | c.620_621insAAGTAGT | p.Asp207GlufsTer6 | p.D207Efs*6 | Q9BSJ5 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |